There is a clear need to more deeply interrogate the role of the ALKF1174L mutation on vascular morphogenesis and architecture, which may be a major determinant of impaired drug delivery and a contributing factor to the poor prognosis of children with ALKF1174L-mutated MYCN-amplified neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.